Transplant Diagnostics Market: Global Market Estimation, Dynamics, Trends, Competitor Analysis 2017-2021 and Forecast 2022-2028

$ PRICE - $ 3,000.00$ 8,900.00

Transplant Diagnostics Market by Technology (Molecular Assay Technologies (PCR-Based Molecular Assays (Real-time PCR, Sequence-specific Primer-PCR, Sequence-specific Oligonucleotide-PCR, Other PCR-based Molecular Assays), Sequencing-based Molecular Assays (Sanger Sequencing, Next Generation Sequencing, Other Sequencing-based Molecular Assays), Non-molecular Assay Technologies), By Product & Service (Reagents & Consumables, Instruments, Software & Services), By Transplant Type (Solid Organ Transplantation (Kidney Transplantation, Liver Transplantation, Heart Transplantation, Lung Transplantation, Pancreas Transplantation, Other Organ Transplantations), Stem Cell Transplantation, Soft Tissue Transplantation, Bone marrow Transplantation) By Application (Diagnostic Applications (Pre-transplantation Diagnostics, (Infectious Disease Testing, Histocompatibility Testing, Blood Profiling), Post-transplantation Diagnostics), Research Applications), By End User (Independent Reference Laboratories, Hospitals & Transplant Centers, Research Laboratories & Academic Institutes) and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category:

Report

Description

The transplant diagnostics market is valued at USD 4.1 billion in 2021 and is poised to grow at a significant CAGR of 7.8% over 2022–2028. One of the main factors driving the expansion of the market under study is the increase in organ donation. In January 2021, more than 12,500 people donated one or more organs in 2020, up 6% from the year before, according to figures released by the Association of Organ Procurement Organizations (AOPO). Over 36,500 organs were donated from deceased donors in 2020, an increase of nearly 2% compared to the previous year. For the seventh consecutive year, these recovered organs saved more lives more than 33,000 than they did the year before. Donation after Circulatory Death (DCD) contributions also saw significant increases; they totalled more than 3,000 donors, an 18% rise from the previous year. Increased transplant diagnostic testing will result from increased organ donation, propelling market expansion. The diagnosis of pulmonary function and general health is emphasized much in the context of heart transplants. The diagnostics have considerably improved over the last ten years due to businesses dedicated themselves to creating better HLA typing technologies, antibody monitoring, equipment, and software. This is rapidly employed for diagnostic purposes during organ transplantation across various body parts. Multispecialty hospitals in developed markets are doing many more transplant procedures due to technical developments and expanding financial opportunities made possible by public-private partnerships. To assess the level of infection inside an organ, the diagnosis for transplantation is carried out at the donor and patient’s ends. Additionally, several significant players are releasing new products on the market, which is anticipated to further fuel market expansion. For instance, in September 2021, Thermo Fisher Scientific added two new products to its range of transplant diagnostics during the American Society for Histocompatibility and Immunogenetics (ASHI) annual meeting.

Recent Market Developments:

In March 2022, Immucor Inc., a US-based transfusion and transplantation diagnostics company, announced the launch of MIA FORA® NGS EXPRESS HLA Typing Software and LIFECODES® LSA Class I and Class II Assays, two additions to its transplant diagnostics portfolio.

Transplant Diagnostics Market

MARKET SUMMARY
-
7.8% CAGR
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 7.8%
  • Largest Market– North America
  • Fastest Growing Market– Asia Pacific

Transplant Diagnostics Market

  • The transplant diagnostics market report gives comprehensive outlook on semen analysis across the globe with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.
  • The transplant diagnostics market report gives historical, current, and future market sizes (US$ Mn) on the basis of product type, application, end user and geography.
Key Players
  • Cylex Inc
  • LXN Corporation
  • Horiba Medical
  • Alpha Laboratories
  • Otsuka Holdings Co Ltd
Transplant Diagnostics Market Dynamics

A significant aspect driving demand for diagnostics before the surgery is the rise in organ transplants. There has always been a greater need for transplants than there are available organs. However, the market will likely profit from in-depth field studies and analyses to close this gap. An increase in the number of people with chronic illnesses that frequently cause organ failure is driving the rising demand for transplant surgeries. Personalized medicine and stem cell therapy are also becoming more popular, increasing the demand for transplant diagnostics. Improved and sophisticated diagnostic methods are required due to the risks and complexity of organ transplantation. Due to an increasing need for high-throughput diagnostic tools with improved accuracy, Next-Generation Sequencing (NGS) technology is quickly replacing traditional diagnostic approaches, such as serological techniques used in Human Leukocyte Antigen (HLA) type. However, the scarcity of available organs for transplant procedures, difficulties with HLA sequencing, and general ignorance restrain market expansion.


North-America Got Significant Share

Transplant Diagnostics Market

The transplant diagnostics market in North America are likely to hold a significant revenue share in 2021, and, in the following years, it is predicted to increase rapidly. North America holds the most significant market share due to its robust healthcare industry and substantial financial commitment to acquiring cutting-edge diagnostic equipment. Furthermore, due to attractive reimbursement policies, the North American transplant diagnostics market is being driven by the availability of experienced specialists and high surgical costs. The European Commission's initiatives for organ harvesting have made donated organs available. The availability of the European donor card and rising public awareness have further increased the region's organ donation rate.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Key Features of the Report

  • The transplant diagnostics market report provides granular level information about the market size, regional market share, historic market (2016-2021) and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Transplant Diagnostics Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The transplant diagnostics market is projected to expand at a CAGR of 7.8% during the forecast period.

Abbott Laboratories Inc., Bio-Rad Laboratories Inc., Hoffmann-La Roche, Ltd., Illumina, Inc., Immucor, Inc., Linkage Biosciences

North America is the fastest-growing region for transplant diagnostics market


Report

Table Of Content


Report

Company Profile

  • LXN Corporation
  • Horiba Medical
  • Alpha Laboratories
  • Cylex Inc
  • Otsuka Holdings Co Ltd
  • Laboratory Corporation of America Holdings
  • Randox Laboratories Ltd
  • Thermo Fisher Scientific Inc
  • TransMedics, Inc.
  • Medtronic
  • Hoffmann-La Roche Ltd.
  • Novartis AG
  • Zimmer Biomet
  • Pfizer Inc.
  • Preservation Solutions, Inc
  • Sanofi, Terumo Corporation
  • Stryker

Description

The transplant diagnostics market is valued at USD 4.1 billion in 2021 and is poised to grow at a significant CAGR of 7.8% over 2022–2028. One of the main factors driving the expansion of the market under study is the increase in organ donation. In January 2021, more than 12,500 people donated one or more organs in 2020, up 6% from the year before, according to figures released by the Association of Organ Procurement Organizations (AOPO). Over 36,500 organs were donated from deceased donors in 2020, an increase of nearly 2% compared to the previous year. For the seventh consecutive year, these recovered organs saved more lives more than 33,000 than they did the year before. Donation after Circulatory Death (DCD) contributions also saw significant increases; they totalled more than 3,000 donors, an 18% rise from the previous year. Increased transplant diagnostic testing will result from increased organ donation, propelling market expansion. The diagnosis of pulmonary function and general health is emphasized much in the context of heart transplants. The diagnostics have considerably improved over the last ten years due to businesses dedicated themselves to creating better HLA typing technologies, antibody monitoring, equipment, and software. This is rapidly employed for diagnostic purposes during organ transplantation across various body parts. Multispecialty hospitals in developed markets are doing many more transplant procedures due to technical developments and expanding financial opportunities made possible by public-private partnerships. To assess the level of infection inside an organ, the diagnosis for transplantation is carried out at the donor and patient’s ends. Additionally, several significant players are releasing new products on the market, which is anticipated to further fuel market expansion. For instance, in September 2021, Thermo Fisher Scientific added two new products to its range of transplant diagnostics during the American Society for Histocompatibility and Immunogenetics (ASHI) annual meeting.

Recent Market Developments:

In March 2022, Immucor Inc., a US-based transfusion and transplantation diagnostics company, announced the launch of MIA FORA® NGS EXPRESS HLA Typing Software and LIFECODES® LSA Class I and Class II Assays, two additions to its transplant diagnostics portfolio.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX